Vcare 2022 Annual Review
Published Time:
2023-01-20 17:39
Source:
I. Corporate Development and Infrastructure
① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd.
② CDMO Business Technology Center completed and operational.
③ Established new technology platform laboratories.
④ Built a new Innovative Drug Synthesis Technology Center.
II. Progress in Innovative Drug R&D Pipeline
① Vicagrel completed subject enrollment for key clinical trials.
② VC004 clinical trials advanced steadily with significant efficacy results.
③ VC005 obtained regulatory approval for multiple expanded indications.
④ Multiple preclinical projects progressed rapidly.
III. Drug R&D Services Sustained Growth
① CRO/CDMO service revenue exceeded RMB 300 million.
② New CRO/CDMO contracts signed valued at nearly RMB 500 million.
IV. Corporate Financing Status
① Successfully closed Series A financing totaling ~RMB 370 million.
② Completed Series B financing exceeding RMB 200 million.
V. Talent Development Initiatives
① Expanded workforce by 200+, reaching nearly 600 employees.
② Completed nearly 50 employee promotions.
③ Conducted ~80 employee training sessions.
④ Held management skills enhancement workshop.
⑤ Established strategic partnerships with multiple universities.
⑥ Launched 2nd employee equity incentive plan, covering ~120 employees.
VI. Awards & Honors
①Jiangsu Vcare Honored As: Nanjing Nurtured Unicorn Enterprise; Jiangsu 2022 Specialized, Refined, Unique, and Innovative SME; Top 30 in Nanjing High-Tech Zone Enterprise Innovation Index
②Nanjing Vcare Honored As: National Sci-Tech SME; Top 20 CRO Enterprises in China’s Pharmaceutical Industry
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn